Last reviewed · How we verify

Curium US LLC — Portfolio Competitive Intelligence Brief

Curium US LLC pipeline: 0 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Copper Cu 64 PSMA I&T Copper Cu 64 PSMA I&T phase 3 Radiopharmaceutical; PSMA-targeted theranostic agent PSMA (Prostate-Specific Membrane Antigen) Oncology
Abiraterone with Prednisone or Enzalutamide Abiraterone with Prednisone or Enzalutamide phase 3 CYP17A1 inhibitor (abiraterone) + androgen receptor antagonist (enzalutamide) + glucocorticoid (prednisone) CYP17A1 (abiraterone); androgen receptor (enzalutamide); glucocorticoid receptor (prednisone) Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Curium US LLC:

Cite this brief

Drug Landscape (2026). Curium US LLC — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/curium-us-llc. Accessed 2026-06-10.

Related